Liquidia Co. (NASDAQ:LQDA) Stake Cut by Findell Capital Management LLC

Findell Capital Management LLC lessened its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 3.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,080,000 shares of the company's stock after selling 113,539 shares during the quarter. Liquidia accounts for 14.8% of Findell Capital Management LLC's portfolio, making the stock its 2nd largest position. Findell Capital Management LLC owned about 3.64% of Liquidia worth $36,221,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Liquidia in the 4th quarter valued at $59,000. Summit Investment Advisors Inc. increased its holdings in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after acquiring an additional 1,719 shares during the period. D. E. Shaw & Co. Inc. purchased a new position in shares of Liquidia in the 4th quarter valued at $142,000. EntryPoint Capital LLC purchased a new position in shares of Liquidia in the 4th quarter valued at $154,000. Finally, Bayesian Capital Management LP purchased a new position in shares of Liquidia in the 4th quarter valued at $163,000. Institutional investors own 64.54% of the company's stock.

Liquidia Stock Performance

Shares of LQDA traded down $0.03 during midday trading on Friday, hitting $15.32. 753,157 shares of the stock were exchanged, compared to its average volume of 1,004,427. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.81. The stock has a fifty day simple moving average of $14.25 and a 200 day simple moving average of $13.18. The firm has a market cap of $1.31 billion, a P/E ratio of -9.40 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities research analysts forecast that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 5,964 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the sale, the general counsel now directly owns 570,301 shares in the company, valued at $7,738,984.57. This trade represents a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. This trade represents a 1.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,138 shares of company stock worth $450,233 over the last ninety days. Corporate insiders own 26.50% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on LQDA shares. Raymond James boosted their target price on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research note on Friday. Scotiabank restated an "outperform" rating on shares of Liquidia in a research note on Monday, May 5th. HC Wainwright restated a "buy" rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Finally, Needham & Company LLC restated a "buy" rating and set a $25.00 target price on shares of Liquidia in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $27.13.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).